跳至主要内容
临床试验/NCT00823199
NCT00823199已完成不适用

An Open Trial of Allopurinol in Patients With Poorly Responsive Schizophrenia

Bronx Psychiatric Center0 个研究点目标入组 10 人开始时间: 2005年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
10
主要终点
Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia

研究概览

简要总结

This is a four week open label trial of ALLOPURINOL to the treatment regime of ten (10) poorly responsive patients with schizophrenia, monitoring their response and side-effects. No change in medication is required.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with schizophrenia and poor response (no prospect of discharge because of symptoms)

排除标准

  • Renal or liver disease
  • Hypertension
  • Taking thiazides or ACE inhibitors

研究组 & 干预措施

Allopurinal treatment

Experimental

Allopurinal 300mg once daily by mouth for four weeks

干预措施: Allopurinal (Drug)

结局指标

主要结局

Change in Positive and Negative Syndrome Scale (PANSS) Measures Symptoms of Schizophrenia

时间窗: baseline and 4 weeks

Symptom scale Score 30 (best, no symptoms of schizophrenia) to 210 (worst)

次要结局

  • Simpson Angus Scale for Parkinsonism(baseline and 4 weeks)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Nigel Bark MD

Director Schizophrenia Research

Bronx Psychiatric Center

相似试验